Cargando…

Pembrolizumab as a monotherapy or in combination with platinum-based chemotherapy in advanced non-small cell lung cancer with PD-L1 tumor proportion score (TPS) ≥50%: real-world data

Both pembrolizumab (P) and combination of pembrolizumab with platinum-based chemotherapy (PCT) represent standard 1(st)-line options for advanced non-small cell lung cancer (aNSCLC) with PD-L1 tumor proportion score (TPS) ≥50%. The two strategies have never been compared in a randomized trial. 256 c...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dudnik, Elizabeth, Moskovitz, Mor, Rottenberg, Yakir, Lobachov, Anastasiya, Mandelboim, Rinat, Shochat, Tzippy, Urban, Damien, Wollner, Mira, Nechushtan, Hovav, Rotem, Ofer, Zer, Alona, Daher, Sameh, Bar, Jair
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7849771/ https://www.ncbi.nlm.nih.gov/pubmed/33552685 http://dx.doi.org/10.1080/2162402X.2020.1865653

Ejemplares similares

Real-world survival outcomes with immune checkpoint inhibitors in large-cell neuroendocrine tumors of lung
por: Dudnik, Elizabeth, et al.
Publicado: (2021)

BAP1-Altered Malignant Pleural Mesothelioma: Outcomes With Chemotherapy, Immune Check-Point Inhibitors and Poly(ADP-Ribose) Polymerase Inhibitors
por: Dudnik, Elizabeth, et al.
Publicado: (2021)

Tyrosine Kinase Inhibitors as a Treatment of Symptomatic CNS Metastases in Oncogene-Driven NSCLC
por: Gal, Omer, et al.
Publicado: (2020)

ALK Inhibitors or Chemotherapy for Third Line in ALK-positive NSCLC? Real-world Data
por: Moskovitz, Mor, et al.
Publicado: (2022)

The Impact of Comprehensive Genomic Profiling (CGP) on the Decision-Making Process in the Treatment of ALK-Rearranged Advanced Non-Small Cell Lung Cancer (aNSCLC) After Failure of 2(nd)/3(rd)-Generation ALK Tyrosine Kinase Inhibitors (TKIs)
por: Raphael, Ari, et al.
Publicado: (2022)

Liquid First Is “Solid” in Naïve Non-Small Cell Lung Cancer Patients: Faster Turnaround Time With High Concordance to Solid Next-Generation Sequencing
por: Sehayek, Or, et al.
Publicado: (2022)

Long term follow-up of EGFR mutated NSCLC cases
por: Rennert, Gad, et al.
Publicado: (2020)

Intensity‐modulated radiotherapy is a safe and effective treatment for localized malignant pleural mesothelioma
por: Simon, Michael, et al.
Publicado: (2018)

Arterial and Venous Thromboembolism in ALK-Rearrangement-Positive Non-small Cell Lung Cancer: A Population-Based Cohort Study
por: Icht, Oded, et al.
Publicado: (2023)

Osimertinib in advanced EGFR-mutant lung adenocarcinoma with asymptomatic brain metastases: an open-label, 3-arm, phase II pilot study
por: Peled, Nir, et al.
Publicado: (2021)

Gut microbial signature in lung cancer patients highlights specific taxa as predictors for durable clinical benefit
por: Haberman, Yael, et al.
Publicado: (2023)

Can Ipilimumab restore immune response in advanced NSCLC after progression on anti‐PD‐1/PD‐L1 agents?
por: Sternschuss, Michal, et al.
Publicado: (2020)

Durvalumab after concurrent chemotherapy and high-dose radiotherapy for locally advanced non-small cell lung cancer
por: Landman, Yosef, et al.
Publicado: (2021)

Oxaliplatin-Induced Pulmonary Toxicity in Gastrointestinal Malignancies: Two Case Reports and Review of the Literature
por: Moskovitz, Mor, et al.
Publicado: (2015)

Chemoradiation followed by adjuvant durvalumab in stage III non–small cell lung cancer: Real‐world comparison of treatment outcomes to historical controls treated with chemoradiation alone
por: Saad, Akram, et al.
Publicado: (2022)

BRCA mutations detected by tumour next-generation sequencing in non-small cell lung cancer: impact on response to therapy and disease course
por: Tschernichovsky, Roi, et al.
Publicado: (2023)

Clinical Characteristics, Response to Platinum-Based Chemotherapy and Poly (Adenosine Phosphate-Ribose) Polymerase Inhibitors in Advanced Lung Cancer Patients Harboring BRCA Mutations
por: Arnon, Johnathan, et al.
Publicado: (2023)

The TPS begins to shine
Publicado: (2015)

Correlations between pathogenic variants in DNA repair genes and anticancer treatment efficacy in stage IV non‐small cell lung cancer: A large real‐world cohort and review of the literature
por: Averbuch, Itamar, et al.
Publicado: (2023)

Dose escalation of osimertinib for intracranial progression in EGFR mutated non-small-cell lung cancer with brain metastases
por: Goldstein, Iris M, et al.
Publicado: (2020)

Blood-Derived Exosomal hTERT mRNA in Patients with Lung Cancer: Characterization and Correlation with Response to Therapy
por: Rotem, Ofer, et al.
Publicado: (2023)

Identification and characterization of novel sesquiterpene synthases TPS9 and TPS12 from Aquilaria sinensis
por: Yu, Cuicui, et al.
Publicado: (2023)

The prevalence of masked hypertension in patients with lone atrial fibrillation: a cross sectional analytical study
por: Ayalon-Dangur, Irit, et al.
Publicado: (2023)

The impact of endogenous estrogen exposures on the characteristics and outcomes of estrogen receptor positive, early breast cancer
por: Korzets, Yasmin, et al.
Publicado: (2021)

Alternate Pembrolizumab Dosing Interval in Advanced NSCLC with PD-L1 TPS ≥ 50%: 3 Weekly Compared to 6 Weekly Dosing
por: Jones, Lauren, et al.
Publicado: (2022)

Role of Nudt2 in Anchorage-Independent Growth and Cell Migration of Human Melanoma
por: Hidmi, Sana’, et al.
Publicado: (2023)

Seasonal Changes in the Incidence of Transient Global Amnesia
por: Keret, Ophir, et al.
Publicado: (2016)

The chromosome-scale genome of Phoebe bournei reveals contrasting fates of terpene synthase (TPS)-a and TPS-b subfamilies
por: Han, Xiao, et al.
Publicado: (2022)

FGFR Fusions as an Acquired Resistance Mechanism Following Treatment with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors (EGFR TKIs) and a Suggested Novel Target in Advanced Non-Small Cell Lung Cancer (aNSCLC)
por: Raphael, Ari, et al.
Publicado: (2022)

The concordance of treatment decision guided by OncotypeDX and the PREDICT tool in real‐world early‐stage breast cancer
por: Goldstein, Daniel A., et al.
Publicado: (2020)

Prognostic impact of HER2-low expression in hormone receptor positive early breast cancer
por: Mutai, Raz, et al.
Publicado: (2021)

Real-world experience with capmatinib in MET exon 14-mutated non-small cell lung cancer (RECAP): a retrospective analysis from an early access program
por: Illini, Oliver, et al.
Publicado: (2022)

Posttransplantation anemia in kidney transplant recipients: A retrospective cohort study
por: Gafter-Gvili, Anat, et al.
Publicado: (2017)

Genome-Wide Identification and Expression Profile of TPS Gene Family in Dendrobium officinale and the Role of DoTPS10 in Linalool Biosynthesis
por: Yu, Zhenming, et al.
Publicado: (2020)

Treatment inferred from mutations identified using massive parallel sequencing leads to clinical benefit in some heavily pretreated cancer patients
por: Zick, Aviad, et al.
Publicado: (2017)

Lung Cancer in Young Patients: Higher Rate of Driver Mutations and Brain Involvement, but Better Survival
por: Suidan, Anna May, et al.
Publicado: (2019)

SCLC, Paraneoplastic Dermatomyositis, Positive Transcription Intermediary Factor 1-γ, and Point Mutation in the Transcription Intermediary Factor 1-γ Coding Gene: A Case Report
por: Arnon, Johnathan, et al.
Publicado: (2021)

The Association between Treatment for Metabolic Disorders and Breast Cancer Characteristics
por: Goldvaser, Hadar, et al.
Publicado: (2016)

The association between smoking and breast cancer characteristics and outcome
por: Goldvaser, Hadar, et al.
Publicado: (2017)

MrTPS3 and MrTPS20 Are Responsible for β-Caryophyllene and α-Pinene Production, Respectively, in Red Bayberry (Morella rubra)
por: Wang, Yan, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_6i0q0e64ueslo4m3n69fm2fqst